DSM and ADM announced that they have reached an agreement in a patent infringement dispute concerning DSM’s US Patents 5,648,261 and 5,879,927 and ADM’s Ecotone® Phaffia Astaxathin product.
Under the terms of the parties’ agreement, ADM has entered into a license
agreement with DSM and will continue to provide the Ecotone® product to the
market. The financial terms of the agreement were not disclosed.
Klop, DSM’s General Manager of Intellectual Property, noted that “DSM values its
significant intellectual property portfolio and it is pleased that a settlement
was reached with ADM.”
2/3 articles remaining | Register to continue reading.